Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.

Julio RosenstockAhmed A KolkailahDarren K McGuireMark A EspelandMichaela MattheusEgon PfarrSøren S LundNikolaus Marxnull null

Published in: Diabetes, obesity & metabolism (2023)

Across the severity spectrum, linagliptin substantially reduced the hypoglycaemic burden versus glimepiride in patients with relatively early type 2 diabetes at increased cardiovascular risk.

Keyphrases

type diabetes
cardiovascular disease
phase iii
study protocol
glycemic control
clinical trial
phase ii
insulin resistance
risk factors
randomized controlled trial
open label
metabolic syndrome
weight loss